Management of Hypomethylating Agent (HMA) Failure in Myelodysplastic Syndromes (MDS)

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: May 07, 2021
Expiration Date: May 07, 2022

Expected time to complete this activity as designed: 15 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Join Dr. Jamile Shammo as she explores challenges and advances in the management of hypomethylating agent (HMA) failure in myelodysplastic syndromes (MDS). Topics will include potential mechanisms of resistance, distinguishing between HMA failure and HMA-related cytopenia, current standard care following HMA failure, and notable clinical trials for treatment of MDS patients with HMA failure.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Discuss the challenges associated with failure of hypomethylating agents (HMAs) in the treatment of high-risk MDS
  • Outline current standard of care and challenges in achieving positive outcomes for patients with high-risk MDS who have failed HMAs
  • Describe promising investigational approaches for the treatment of patients with high-risk MDS following HMA failure

Agenda

Management of Hypomethylating Agent (HMA) Failure in Myelodysplastic Syndromes (MDS) – Jamile M. Shammo, MD, FASCP, FACP

Instructions for Participation and Credit

This activity is eligible for credit through May 07, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Jamile M. Shammo, MD, FASCP, FACP
Professor of Medicine and Pathology
Section of Hematology and Stem Cell Transplantation
Division of Hematology/Oncology
Rush University Medical Center
Chicago, Illinois

Dr. Jamile Shammo received her medical degree from Aleppo Medical School in Syria. She completed residencies in anatomic and clinical pathology, as well as internal medicine at McGaw Medical Center of Northwestern University, Evanston, Illinois. She then completed a fellowship in the Division of Hematology/Oncology at University of Chicago. Dr. Shammo is Professor of Medicine and Pathology in the Section of Hematology and Stem Cell Transplantation, Division of Hematology/Oncology, at Rush University Medical Center in Chicago, Illinois. In her current position, she spearheads the MDS/MPN/Bone Marrow Failure Program.

Dr. Shammo is board certified in anatomic and clinical pathology as well as hematology. She is a fellow of the American Society of Clinical Pathologists and American College of Physicians. As resident education faculty leader, principal investigator of clinical trials in her area of expertise, and as chair of the protocol review and monitoring committee at Rush Cancer Institute, she is heavily involved in education, research, and administrative activities in the Division of Hematology/Oncology. In 2011, Dr. Shammo founded the Chicago MDS/MPN group to facilitate scientific exchange among academic medical centers in Chicago, and has chaired multiple city-wide meetings. She has developed and chaired online CME activities pertaining to MDS, MPN, as well as PNH, and has designed and conducted several investigator-initiated trials in these areas. As an invited speaker, Dr. Shammo lectured at national and international meetings and conferences. In addition, she has authored and contributed to more than 100 publications and served as a reviewer for the Journal of Clinical Oncology and Blood. She received the MDS Foundation ‘Nobility in Science Award’ in 2019.

Accreditation

MediCom CME CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-014-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Jamile Shammo has received honoraria as a consultant from Alexion, Apellis Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Incyte Corporation, Novartis AG, and Sanofi; honoraria related to formal advisory activities from Apellis; as well as speakers’ bureau activities from Alexion, Bristol-Myers Squibb, Incyte, and Sanofi. She has received grant support related to research activities from Alexion, AstraZeneca, Bristol-Myers Squibb, Celgene, CTI BioPharma Corp, Incyte, Kartos Therapeutics, Inc, Novartis, Onconova Therapeutics, and Stemline Therapeutics, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc.

©2021 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.